BRAF Mutation in Albanian Melanoma Patients New Approach from Diagnosis to the Treatment

Daniela Xhemalaj


The incidence of cutaneous melanoma is steadily increasing, mainly in populations of European origin and is thus an important public health issue throughout the world. Cutaneous melanoma is a malignancy with a favorable prognosis if it presents as a localized disease, but with a dramatically worse prognosis if it metastasizes. No effective treatment exists for the group of melanoma patients with metastasizing disease, although several nonspecific chemotherapy regimens and immunotherapies are able to prolong survival at least for a short period of time. Last years has started a new area in the treatment using BRAF mutation inhibitors, especially for patients with BRAF V600E positive, so, also in melanoma is available targeted therapy. This new treatment plays an important role in their survival. The aim of the study: to evaluate the BRAF mutation in patients diagnosed with melanoma. Methods: We analised BRAF mutation in 12 formaline -fixed paraffine embedded (FFPE) tissue of patients diagnosed with melanoma from January to December 2014. Results: From 12 FFPE tissue we found 67 % (n=8) BRAF V600E, 25 % (n=3) BRAF Wild Type, 8% (n=1) BRAF V600K. Conclusions: BRAF V600E mutation is an important molecular target for novel therapeutic approaches in area of targeted therapy of melanoma patients. Patient with unresectable or metastatic melanoma, whith BRAF V600E, can use BRAF – inhibitors, increasing their survival.

Keywords: Albania, melanoma, BRAF mutation, biopsy.

Full Text:




Copyright © 2012-2020 ANGLISTICUM. Journal of the Association-Institute for English Language and American Studies,Tetovo, Republic of North Macedonia.

All Rights Reserved.

The publication is licensed under a Creative Commons License (CC BY)  View Legal Code                                                                                                                 

ISSN (print): 1857-8179. ISSN (online): 1857-8187.

Disclaimer: Articles on Anglisticum have been reviewed and authenticated by the Authors before sending for the publication.

The Journal, Editors and the editorial board are not entitled or liable to either justify or responsible for inaccurate and misleading data if any. It is the sole responsibility of the Author concerned.